» Articles » PMID: 20856845

Emerging Treatments in the Management of Schizophrenia - Focus on Sertindole

Overview
Specialty Pharmacology
Date 2010 Sep 22
PMID 20856845
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The antipsychotic treatment of schizophrenia is still marked by poor compliance, and drug discontinuation; the development of more effective and safer drugs still remains a challenge. Sertindole is a second-generation antipsychotic with high affinity for dopamine D(2), serotonin 5-HT(2A), 5-HT(2C), and α(1)-adrenergic receptors, and low affinity for other receptors. Sertindole undergoes extensive hepatic metabolism by the cytochrome P450 isoenzymes CYP2D6 and CYP3A4 and has an elimination half-life of approximately three days. In controlled clinical trials sertindole was more effective than placebo in reducing positive and negative symptoms, whereas it was as effective as haloperidol and risperidone against the positive symptoms of schizophrenia. The effective dose-range of sertindole is 12-20 mg, administered orally once daily. The most common adverse events are headache, insomnia, rhinitis/nasal congestion, male sexual dysfunction, and moderate weight gain, with few extrapyramidal symptoms and metabolic changes. Sertindole is associated with corrected QT interval prolongation, with subsequent risk of serious arrythmias. Due to cardiovascular safety concerns, sertindole is available as a second-line choice for patients intolerant to at least one other antipsychotic agent. Further clinical studies, mainly direct "head-to-head" comparisons with other second-generation antipsychotic agents, are needed to define the role of sertindole in the treatment of schizophrenia.

Citing Articles

Two Sudden and Unexpected Deaths of Patients with Schizophrenia Associated with Intramuscular Injections of Antipsychotics and Practice Guidelines to Limit the Use of High Doses of Intramuscular Antipsychotics.

Wahidi N, Johnson K, Brenzel A, De Leon J Case Rep Psychiatry. 2016; 2016:9406813.

PMID: 27597919 PMC: 5002457. DOI: 10.1155/2016/9406813.


The influence of atypical antipsychotic drugs on sexual function.

Just M Neuropsychiatr Dis Treat. 2015; 11:1655-61.

PMID: 26185449 PMC: 4501246. DOI: 10.2147/NDT.S84528.


QT dynamics during treatment with sertindole.

Nielsen J, Wang F, Graff C, Kanters J Ther Adv Psychopharmacol. 2015; 5(1):26-31.

PMID: 25653828 PMC: 4315672. DOI: 10.1177/2045125314560738.


The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.

Peuskens J, Pani L, Detraux J, De Hert M CNS Drugs. 2014; 28(5):421-53.

PMID: 24677189 PMC: 4022988. DOI: 10.1007/s40263-014-0157-3.


Effect of epigallocatechin gallate supplementation in schizophrenia and bipolar disorder: an 8-week, randomized, double-blind, placebo-controlled study.

Loftis J, Wilhelm C, Huckans M Ther Adv Psychopharmacol. 2013; 3(1):21-7.

PMID: 23983989 PMC: 3736959. DOI: 10.1177/2045125312464103.


References
1.
Peuskens J, Moore N, Azorin J, Toumi M, Cochran J . The European sertindole safety and exposure survey: a follow-up study of 8600 patients. Pharmacoepidemiol Drug Saf. 2007; 16(7):804-11. DOI: 10.1002/pds.1425. View

2.
Kasper S . Do we need another atypical antipsychotic?. Eur Neuropsychopharmacol. 2008; 18 Suppl 3:S146-52. DOI: 10.1016/j.euroneuro.2008.04.006. View

3.
Leucht S, Corves C, Arbter D, Engel R, Li C, Davis J . Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2008; 373(9657):31-41. DOI: 10.1016/S0140-6736(08)61764-X. View

4.
Titier K, Canal M, Deridet E, Abouelfath A, Gromb S, Molimard M . Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice. Toxicol Appl Pharmacol. 2004; 199(1):52-60. DOI: 10.1016/j.taap.2004.03.016. View

5.
Perquin L, Steinert T . A review of the efficacy, tolerability and safety of sertindole in clinical trials. CNS Drugs. 2004; 18 Suppl 2:19-30. DOI: 10.2165/00023210-200418002-00003. View